Browse

Genetic Polymorphisms in the Folate Pathway Are Associated with Efficacy and Toxicity of Methotrexate in Pediatric Osteosarcoma
소아 골육종 환자에서 Folate 대사 연관 유전자 다형성과 Methotrexate 치료 효과 및 독성의 연관성에 관한 연구

Cited 0 time in Web of Science Cited 0 time in Scopus
Authors
박정아
Advisor
신희영
Major
의과대학 의학과
Issue Date
2013-02
Publisher
서울대학교 대학원
Keywords
Osteosarcomamethotrexatefolategeneticpolymorphism
Description
학위논문 (박사)-- 서울대학교 대학원 : 의학과 분자종양의학 전공, 2013. 2. 신희영.
Abstract
Background & Purpose: Osteosarcoma is the most common childhood malignant bone tumor. Efficacy of multi-agent chemotherapy for osteosarcoma including methotrexate, adriamycin and cisplatin may be influenced by multiple cellular pathways. Methotrexate (MTX), one of the main drugs used for osteosarcoma, is a representative folic acid antagonist. Genetic polymorphisms in folate pathway genes are expected to influence the response and toxicity of high-dose MTX therapy in pediatric osteosarcoma, However, there are scarce data available regarding associations between genetic polymorphisms and pediatric osteosarcoma. This study evaluated the effect of common genetic polymorphisms in the folate metabolic pathway on overall survival, event-free survival and histological response to neoadjuvant chemotherapy including high-dose MTX. In addition, whether these genetic polymorphisms affect the concentrations of MTX and toxicity after high-dose MTX therapy for osteosarcoma was investigated.
Methods: Blood and tissue samples from 48 osteosarcoma patients (blood samples from 19 patients, tissue samples from 22 patients, and both blood and tissue samples from 7 patients) who had completed chemotherapy were obtained, and the following polymorphisms were analyzed
RFC1 80G>A, DHFR 829C>T, MTHFR 677C>T, MTHFR 1298A>C, AMPD1 34C>T, ATIC 347C>G, and ITPA 94C>A. Associations between candidate polymorphisms and survival, histological response (tumor necrosis rate) and MTX level and toxicity after high-dose MTX therapy were analyzed.
Results: Event-free survival significantly decreased in DHFR 829 CC homozygote (P=0.045). There were no statistically significant associations between genetic polymorphisms and histological response, however, variant carriers of MTHFR 677C>T had tendency towards poor histological response (P=0.078). MTX concentration was significantly associated with RFC1 80G>A polymorphism (P=0.027). Liver toxicity after high-dose MTX was associated with ATIC 347C>G (P=0.043) and tended to increase in carriers of MTHFR 677C>T (P=0.069). Severe stomatitis was associated with RFC1 80G>A (P=0.012).
Conclusions: This study has demonstrated that several genetic polymorphisms in folate pathway can significantly influence therapeutic response, clinical outcome and MTX level and toxicity after high-dose MTX therapy in osteosarcoma patients. If these associations are independently validated, these variants could be used as genetic predictors of clinical outcome in the treatment of patients with osteosarcoma, aiding the development of tailored therapeutic approaches.
Language
English
URI
https://hdl.handle.net/10371/121886
Files in This Item:
Appears in Collections:
College of Medicine/School of Medicine (의과대학/대학원)Dept. of Medicine (의학과)Theses (Ph.D. / Sc.D._의학과)
  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse